Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032, says analyst

Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at around $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets (USA, France, Germany, Italy, Spain, UK, and Japan).

US pharma major Eli Lilly’s (NYSE: LLY) Jaypirca (pirtobrutinib) is forecast to become the market leader in BTK inhibitors for CLL, garnering nearly 60% share with about $3 billion in sales by 2032, according to sector analytics company GlobalData.

Additionally, the generic erosion of AbbVie (NYSE: ABBV) and Johnson & Johnson’s (NYSE: JNJ) Imbruvica (ibrutinib), a first-generation BTK inhibitor and the market leader since 2013, is expected to affect sales, with its market exclusivity ending in the US by 2028 and the 5EU) by 2029. In the price negotiations program between manufacturers and Medicare under the Biden administration, Imbruvica is the only cancer drug on the list that needs to slash its sale price in the US in 2026.